RBC keeps CryoCath at outperform

CryoCath Technologies was maintained at an outperform rating, speculative risk, by RBC Capital Markets analyst Phil Nalbone on news that the company's chief executive resigned. The company is looking for a new chief financial officer as well as a new CEO. The CEO's departure may be unnerving but does not necessarily signal a decline in CryoCath's long-term prospects, according to the analyst. Shares of the Montreal-based medical technology company were down 13 cents, or 3.90%, at C$3.20 on volume of 101,000 shares versus the three-month running average of 37,217 shares. (Toronto: CYT TO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.